These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12842959)

  • 21. development of a therapeutic approach to rare cancers in children: the Children's Oncology Group experience.
    Pashankar FD; Rodriguez-Galindo C; Pappo A
    J Pediatr Hematol Oncol; 2012 May; 34 Suppl 2():S37-8. PubMed ID: 22525404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.
    Dehbi HM; Royston P; Hackshaw A
    BMJ; 2017 May; 357():j2250. PubMed ID: 28546261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised controlled trials: the importance of sample size.
    Sedgwick P
    BMJ; 2015 Mar; 350():h1586. PubMed ID: 25801454
    [No Abstract]   [Full Text] [Related]  

  • 24. To make progress in rare cancers, patients must lead the way.
    Dockser Marcus A
    J Clin Oncol; 2009 Jun; 27(16):2575-7. PubMed ID: 19414666
    [No Abstract]   [Full Text] [Related]  

  • 25. Limitations of randomized clinical trials in chronic diseases: explanations and recommendations.
    Pincus T
    Adv Mind Body Med; 2002; 18(2):14-21. PubMed ID: 12629874
    [No Abstract]   [Full Text] [Related]  

  • 26. Exposure analysis of dichotomous response measures in long-term studies.
    Peace KE; Carter WH
    J Biopharm Stat; 1993 Mar; 3(1):129-40. PubMed ID: 8485533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The design and use of cluster randomised controlled trials in evaluating injury prevention interventions: part 2. Design effect, sample size calculations and methods for analysis.
    Coupland C; DiGuiseppi C
    Inj Prev; 2010 Apr; 16(2):132-6. PubMed ID: 20363822
    [No Abstract]   [Full Text] [Related]  

  • 28. A unifying strategy for clinical trials in rare urological malignancy.
    Nicholson S
    Nat Clin Pract Urol; 2008 Dec; 5(12):652-3. PubMed ID: 19015645
    [No Abstract]   [Full Text] [Related]  

  • 29. Regarding paper "Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance" by Lui K. J. and Chang K. C.
    Vach W
    Biom J; 2007 Aug; 49(4):627-9; author reply 630-1. PubMed ID: 17722194
    [No Abstract]   [Full Text] [Related]  

  • 30. [Orphan diseases: evaluations of new treatments].
    Bergmann JF; Delcey V; Champion K
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S202-5. PubMed ID: 18228689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fallacies in clinical cardiovascular trials.
    Swedberg K
    Heart; 2009 Sep; 95(17):1464-8. PubMed ID: 19684197
    [No Abstract]   [Full Text] [Related]  

  • 32. A note on non-parametric ANCOVA for covariate adjustment in randomized clinical trials.
    Chen X
    Stat Med; 2005 May; 24(9):1449-52; author reply 1452. PubMed ID: 15812844
    [No Abstract]   [Full Text] [Related]  

  • 33. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interpretation of negative clinical trials].
    López-Jiménez F; Paniagua D; Lamas GA
    Rev Invest Clin; 1998; 50(5):435-40. PubMed ID: 9949676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?
    Bria E; Di Maio M; Cuppone F; Nisticò C; Cognetti F; Giannarelli D
    J Clin Oncol; 2007 Feb; 25(5):605-6; author reply 606-7. PubMed ID: 17290074
    [No Abstract]   [Full Text] [Related]  

  • 36. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A guide to sample size and interim analysis in clinical trials.
    Rademaker AW
    Contemp Urol; 1994 Feb; 6(2):43-4. PubMed ID: 10146676
    [No Abstract]   [Full Text] [Related]  

  • 39. Diagnostics for assumptions in moderate to large simple clinical trials: do they really help?
    Ganju J
    Stat Med; 2006 May; 25(10):1799-800. PubMed ID: 16639774
    [No Abstract]   [Full Text] [Related]  

  • 40. [Design and conduct of randomized controlled trials (RCTs)].
    Park DH; Baik SK
    Korean J Hepatol; 2006 Sep; 12(3):309-14. PubMed ID: 16998284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.